Regen BioPharmaRGBP -25.00% 3-Year RORE % is -24.00 as of Mar. 2026. The stock has 7 warning signs investors should review. Among 1,295 Biotechnology companies, Regen BioPharma ranks worse than 62.39% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Regen BioPharma's 3-Year RORE % for the quarter that ended in Mar. 2026 was -24.00%.
The industry rank for Regen BioPharma's 3-Year RORE % or its related term are showing as below:
RGBP's 3-Year RORE % is ranked worse than 62.39% of 1295
companies
in the Biotechnology industry
Industry Median: -11.53
vs RGBP: -24.00
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Regen BioPharma 3-Year RORE % Related Terms
Regen BioPharma 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Regen BioPharma's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGBP vs SIGY, ENDV, CNBX: 3-Year RORE % Comparison
For the Biotechnology subindustry, Regen BioPharma's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regen BioPharma 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regen BioPharma's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Regen BioPharma's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Regen BioPharma (RGBP) has a 3-Year RORE % of -24.00 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Regen BioPharma and its competitors. According to the industry distribution chart, Regen BioPharma ranks #808 out of 1295 companies in the Biotechnology industry, placing it in the top 62.4%.
Is Regen BioPharma's 3-Year RORE % too high?
Regen BioPharma's current 3-Year RORE % is -24.00. Based on the distribution chart, Regen BioPharma ranks #808 out of 1295 companies in the Biotechnology industry, which is below the industry midpoint.
How does Regen BioPharma's 3-Year RORE % compare to SIGY and ENDV?
According to the Biotechnology industry distribution chart, Regen BioPharma ranks #808 out of 1295 companies for 3-Year RORE %. This places Regen BioPharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Regen BioPharma and its competitors. Regen BioPharma's current 3-Year RORE % is -24.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99.3% below its estimated fair value. The current 3-Year RORE % is -24.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current 3-Year RORE % is -24.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGBP has been successfully added to your 